Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.

Autor: Singh D; Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK., Brightling CE; Institute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University of Leicester, Leicester, UK., Rabe KF; LungenClinic Grosshansdorf, Grosshansdorf, Germany; Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; Christian-Albrechts University of Kiel, Kiel, Germany., Han MK; University of Michigan, Ann Arbor, MI, USA., Christenson SA; Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, CA, USA., Drummond MB; Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Papi A; Department of Translational Medicine, University of Ferrara, Ferrara, Italy., Pavord ID; Respiratory Medicine, National Institute for Health and Care Research Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Molfino NA; Global Development, Amgen, Thousand Oaks, CA, USA., Almqvist G; Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Kotalik A; Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Hellqvist Å; Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Gołąbek M; Late‑stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland., Sindhwani NS; Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA., Ponnarambil SS; Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Electronic address: sandhia.ponnarambil@astrazeneca.com.

Publikováno v: The Lancet. Respiratory medicine [Lancet Respir Med] 2024 Dec 06. Date of Electronic Publication: 2024 Dec 06.

Early Albumin Infusion Is Associated With Greater Survival to Discharge Among Patients With Sepsis/Septic Shock Who Develop Severe Acute Kidney Injury Among Patients With Sepsis/Septic Shock Who Develop Severe Acute Kidney Injury.

Autor: Raghunathan K; Department of Anesthesiology, Duke University, Durham, NC., Kempker JA; Department of Medicine, Emory University, Atlanta, GA., Davis EA; Grifols Shared Services North America (SSNA), Research Triangle Park, Durham, NC., Sindhwani NS; Grifols Shared Services North America (SSNA), Research Triangle Park, Durham, NC., Telang S; Boston Strategic Partners, Inc, Boston, MA., Lodaya K; Boston Strategic Partners, Inc, Boston, MA., Martin GS; Department of Medicine, Emory University, Atlanta, GA.

Publikováno v: Critical care explorations [Crit Care Explor] 2022 Dec 12; Vol. 4 (12), pp. e0793. Date of Electronic Publication: 2022 Dec 12 (Print Publication: 2022).

Epithelial clara cell injury occurs in bronchiolitis obliterans syndrome after human lung transplantation.

Autor: Kelly FL; Division of Pulmonary and Critical Care Medicine-Duke University Medical Center, Durham, North Carolina, USA., Kennedy VE, Jain R, Sindhwani NS, Finlen Copeland CA, Snyder LD, Eu JP, Meltzer EB, Brockway BL, Pavlisko E, Stripp BR, Palmer SM

Publikováno v: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2012 Nov; Vol. 12 (11), pp. 3076-84. Date of Electronic Publication: 2012 Aug 06.